Deloitte recognizes BICO as the third fastest-growing company in Sweden in the annual Technology Fast 50 ranking
The leading bio convergence company, BICO, announced today it ranked number three among Sweden's fastest-growing technology companies by this year's Deloitte Sweden Technology Fast 50. Deloitte's annual ranking acknowledges the 50 fastest-growing technology companies based on revenue growth over the last four years.
"The recognition is a confirmation of our rapid global growth and of the potential and interest for our bio convergence offering. I am thankful for the award, and very proud of the commitment of our team members that enables us to continue to create the future of health. I am excited to continue to accelerate and build this company for the future with the team" says Erik Gatenholm, CEO and co-founder BICO.
Founded in 2016, BICO has rapidly grown from one company with one office in Sweden focused on bioink and bioprinters to a global coherent group with an extensive bio convergence offering with more than 1,000 employees in 37 offices. The company today has more than 25,000 instruments installed in more than 65 countries around the globe.
"We are excited to recognise and celebrate the companies in this year's Deloitte Sweden Technology Fast 50. The companies ranked, and the smart solutions and services they provide, reflect Sweden's position at the forefront of innovation, entrepreneurship and digital transformation. Qualifying for a place on the list is a significant achievement and we look forward to seeing what's next for these companies", says Ester Sundström, partner and responsible for Deloitte Sweden Technology Fast 50.
For more information about Deloitte Sweden Technology Fast 50 please visit: fast50.se (http://www.fast50.se/)
For further information, please contact:
Isabelle Ljunggren, Head of Communications
Phone (Sweden): +46 70 830 0890
BICO Press office
Riley Munks, PR Manager: (650) 863-6699
Alyssa D'Orazio, PR Manager: (617) 634-9601
This information was submitted for publication, through the agency of the contact persons set out above, on November 25, 2021, at 5.30 pm (CET).
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.
With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group's instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com